Between-centre differences and treatment effects in randomized controlled trials: A case study in traumatic brain injury by Roozenbeek, B. (Bob) et al.
RESEARCH Open Access
Between-centre differences and treatment effects
in randomized controlled trials: A case study in
traumatic brain injury
Hester F Lingsma1*, Bob Roozenbeek1,2, Pablo Perel3, Ian Roberts3, Andrew IR Maas2 and Ewout W Steyerberg1
Abstract
Background: In Traumatic Brain Injury (TBI), large between-centre differences in outcome exist and many clinicians
believe that such differences influence estimation of the treatment effect in randomized controlled trial (RCTs). The
aim of this study was to assess the influence of between-centre differences in outcome on the estimated
treatment effect in a large RCT in TBI.
Methods: We used data from the MRC CRASH trial on the efficacy of corticosteroid infusion in patients with TBI.
We analyzed the effect of the treatment on 14 day mortality with fixed effect logistic regression. Next we used
random effects logistic regression with a random intercept to estimate the treatment effect taking into account
between-centre differences in outcome. Between-centre differences in outcome were expressed with a 95% range
of odds ratios (OR) for centres compared to the average, based on the variance of the random effects (tau2). A
random effects logistic regression model with random slopes was used to allow the treatment effect to vary by
centre. The variation in treatment effect between the centres was expressed in a 95% range of the estimated
treatment ORs.
Results: In 9978 patients from 237 centres, 14-day mortality was 19.5%. Mortality was higher in the treatment
group (OR = 1.22, p = 0.00010). Using a random effects model showed large between-centre differences in
outcome (95% range of centre effects: 0.27- 3.71), but did not substantially change the estimated treatment effect
(OR = 1.24, p = 0.00003). There was limited, although statistically significant, between-centre variation in the
treatment effect (OR = 1.22, 95% treatment OR range: 1.17-1.26).
Conclusion: Large between-centre differences in outcome do not necessarily affect the estimated treatment effect
in RCTs, in contrast to current beliefs in the clinical area of TBI.
Background
Traumatic brain injury (TBI) is a major health and socio-
economic problem throughout the world. It is the field
with one of the greatest unmet needs in medicine and
public health [1]. Not only is TBI a major cause of death
and disability, incurring great personal suffering to vic-
tims and relatives, but it also leads to huge direct and
indirect costs to society [2].
Many randomized controlled trials (RCTs) have been
performed to investigate the effectiveness of new thera-
pies in TBI, but very few have convincingly demonstrated
benefit [3]. Multiple factors may have contributed to this
disappointing picture, including RCTs in TBI being too
small to detect or refute reliably moderate but clinically
important benefits or hazards of treatment [4]. To design
trials of sufficient size to detect moderate treatment
effects, participation of multiple centres is required.
Considerable between-centre differences in patient out-
come have been reported in TBI [5-7]. Recently it was
shown that a 3.3-fold difference between centres in the
odds of having an unfavourable outcome exist (p <
0.001), which was not explained by random variation or
patient characteristics [8].
Many clinicians in the field of TBI believe that such
between-centre differences in outcome influence the
chances of demonstrating a treatment effect in RCTs
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[7,9]. The aim of this study is to assess the effect of
between-centre differences on estimates of the treatment
effect in a large RCT in TBI.
Methods
Data
We used the individual patient data of the MRC CRASH
trial. The CRASH trial (corticosteroid randomisation
after significant head injury) is a large, international, ran-
domised placebo-controlled trial of the effect of early
administration of 48 h infusion of corticosteroids
(methylprednisolone) on risk of death and disability after
head injury. Patients from 239 centres in 48 countries
were enrolled between April 1999 and May 2004, when
the steering committee stopped recruitment because of a
higher 14 day mortality rate in the treatment group [10].
Analysis
We first assessed whether there were differences in out-
come between the centres in the CRASH trial, using a ran-
dom effect logistic regression model (Appendix 1). In this
model the outcome of a patient is only determined by the
centre that treats the patient. Since some centres only
treat a small number of patients, part of the between-cen-
tre differences are caused by random variation. The ran-
dom effect model estimates the between-centre differences
beyond random variation. The between-centre differences
are expressed as τ2, which is the variance of the random
effects.
Part of the differences between centres may be caused
by the fact that centres are from a particular country.
To separate between-centre differences from between-
country differences we extended the random effect
model with a country level.
Because part of the between-centre effect may be
explained by differences in patient characteristics, we
adjusted the between-centre differences in outcome for
age, Glasgow Coma Scale (GCS) and pupil reactivity at
admission. These are the three main generally accepted
prognostic factors in TBI [11,12]. Age and GCS (a scale
from 1-15) where treated as continuous variables and
pupil reactivity as a binary variable (both pupils reactive
versus one or both unreactive). So now the outcome of a
patient is determined by patient characteristics and
centre.
The differences between centres in outcome were
expressed in a 95% range of odds ratios for centres com-
pared to the average [13]. To avoid confusion with the
odds ratio of the treatment effect we refer to this range
as the 95% centre effect range.
Next we estimated the treatment effect with and with-
out taking the between-centre differences into account.
We first analyzed the univariate effect of the treatment
on 14 day mortality with usual fixed effect logistic
regression. Centre effects were ignored, which is a com-
mon approach also in multicentre trials. We considered
this as the reference strategy.
We furthermore use a random effect model to esti-
mate the treatment effect. The outcome is also deter-
mined by the centre, so the treatment effect is adjusted
for between centre-differences. This approach assumes a
uniform treatment effect across centres. This means we
expect the treatment to have equal effects in each cen-
tre. As a second approach we used a random effect
logistic regression model with interaction between cen-
tre and treatment to asses whether the treatment effect
varied between the centres. The variation in estimated
treatment effect was expressed in a 95% range of the
estimated treatment effect across centres. We compared
the estimates of the treatment effect and the p-values in
the two approaches with the reference strategy.
The random effect estimates of the individual centres
for both outcome and treatment effect were plotted
with 95% posterior intervals.
Statistical analysis where performed in R statistical
software 2.7.2 using the Design and lme4 libraries (R
Foundation for Statistical Computation, Vienna). Ran-
dom effect models were fitted with Adaptive Gaussian
Quadrature with 10 qpoints.
This particular analysis did not need ethical approval.
Results
Descriptives
In total 10,008 patients were included in the RCT. We
excluded 30 patients with missing 14 day outcome,
leaving 9978 patients from 237 centres for the ana-
lyses. After 14 days 1,948 (19.5%) of the patients had
died, with higher mortality in the treatment group.
(Table 1)
Table 1 Baseline characteristics and 14 day mortality of
patients enrolled in the CRASH trial with mortality data
available (n = 9978)
Corticosteroid (n =
4991)
Placebo (n =
4987)
Age (median, interquartile
range)
33, 23-47 32, 23-47
Gender
Male 4060 (81.3%) 4016 (80.5%)
Glasgow Coma Scale
Severe (3-8) 1966 (39.4%) 1966 (39.4%)
Moderate (9-12) 1554 (31.1%) 1479 (29.7%)
Mild (13-14) 1471 (29.5%) 1542 (30.9%)
Pupillary reactivity
Both reactive to light 4272 (85.6%) 4016 (80.5%)
14 day mortality
Dead 1053 (21.1%) 895 (17.9%)
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Between-centre differences
There was a large difference between centres in outcome
(τ2outcome, centre = 0.447, p < 0.00001). The corresponding
95% range of centre effects was 0.27- 3.71 (Table 2). This
means that in centres with the lowest mortality (2.5th per-
centile) the odds of dying was 0.27 times the average,
while in the centres the highest mortality (97.5th percen-
tile) the odds of dying was 3.71 times the average. After
adjustment for age, GCS and pupil reactivity the between-
centre in outcome increased to τ2outcome, centre = 0.620 (p <
0.00001) with a corresponding 95% range of centre effects
of 0.21- 4.68. Figure 1 shows the estimated adjusted odds
ratios for mortality for each centre, compared to the aver-
age, with 95% posterior intervals.
Part of the differences in outcome between centres
were actually differences between countries. When tak-
ing into account that centres are from a particular coun-
try, the range of between-centre differences decreased to
0.39-2.58 (τ2outcome, centre | country = 0.235, p < 0.00001).
The range of between-country differences was 0.26 to
3.88 (τ2outcome, centre | country = 0.470, p < 0.00001).
Treatment effect
In the reference strategy, the univariate fixed effect
logistic regression odds ratio (OR) for treatment was
1.22 (p = 0.0001, Table 3).
Our first approach of adjusting for the between-centre
heterogeneity resulted in an OR for the treatment effect
of 1.24 (p = 0.00003). With our second approach we esti-
mated a varying treatment effect between the centres.
The mean OR was 1.22 (p = 0.00029). The treatment
effect heterogeneity was small, but statistically significant
(τ2treaetment effect = 0.02, p < 0.00001). The corresponding
95% range of the estimated treatment effects across cen-
tres was 1.17-1.26 (Figure 2)
Discussion
Although we found large between-centre differences in
outcome in the CRASH trial, taking these into account
did not substantially change the estimated treatment
effect. Neither did we see major differences in treatment
effect by centre. This study provides no support for the
hypothesis that between-centre differences in outcome
affect the chances of demonstrating a treatment effect in
RCTs, in contrast to current beliefs in this clinical area
[7,9].
Considering differences between centres in outcome
and in estimated treatment effect could be of importance
from two perspectives. First, between-centre heterogene-
ity in the treatment effect between may indicate limited
generalizability, which is of importance for example
when registering a drug in a particular country. In our
study there was no clinically meaningful heterogeneity in
overall treatment effect. Although the between-centre
differences in the treatment effect were statistically signif-
icant, the 95% range was small (1.17-1.26). Clearly, deter-
mining generalizability is not solely a statistical issue but
requires a clinical judgement to the extent to which the
trial results might apply to another population.
Some trials have estimated the heterogeneity of the
treatment effect between centres or countries or regions,
but did not use random effect modelling. The PLATO
study (The Study of Platelet Inhibition and Patient Out-
comes) compared two platelet inhibitors (Ticagrelor ver-
sus Clopidogrel) for prevention of cardiovascular events in
patients with acute coronary syndrome. The overall treat-
ment effect was a hazard ratio (HR) of 0.84 in favour of
Ticagrelor. The treatment effect was also tested in four
different geographic regions separately; Asia-Australia (N
= 1,714), Central-South America (N = 1,237), Europe-
Middle East-Africa (N = 13,859), and North America (N =
1,814). In Europe the estimated HR was 0.80 (95% CI:
0.72-0.90). The HRs in Asia-Australia, Central-South
America were 0.80 and 0.86, both non statistically signifi-
cant. The estimated HR in North America was however
1.25 (95% CI: 0.93-1.67). The authors state that “the differ-
ence in results between patients enrolled in North Amer-
ica and those enrolled elsewhere raises the questions of
whether geographic differences between populations of
patients or practice patterns influenced the effects of the
randomized treatments, although no apparent explana-
tions have been found.”
This interpretation shows the importance to distinct sta-
tistical from clinical reasoning. Although the statistical
analysis showed significant differences between geographic
regions in the PLATO trial, which could be an indication
of limited generalizability, the authors have no biological
or mechanistic explanation for the heterogeneity of the
Table 2 Between-centre and between-country variation in 14 day mortality, unadjusted and adjusted for treatment,
age, GCS, and pupillary reactivity
Unadjusted Adjusted (Conditional)
Tau2 95% range Tau2 95% range
Between-centres 0.447 (p < 0.00001) 0.27-3.71 0.620 (p < 0.00001) 0.21-4.68
Between-counties 0.385 (p < 0.00001) 0.30-3.37 0.642 (p < 0.00001) 0.21-4.81
Combined: Between-centres 0.331 (p < 0.00001) 0.32-3.09 0.235 (p < 0.00001) 0.39-2.58
Between-counties 0.142 (p < 0.00001) 0.48-2.09 0.470 (p < 0.00001) 0.26-3.88
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treatment effect and no heterogeneity was expected on
beforehand. In such a situation were region specific esti-
mates of the treatment effect are desired, or when hetero-
geneity in the treatment effect is expected, we would
recommend to use a random effect model to estimate the
between-region differences in treatment effect. On the
other hand, a limited number of centres, countries or
regions, complicates estimation of the heterogeneity in
treatment effect.
Second, it is thought that heterogeneity between cen-
tres might reduce statistical power to detect the treat-
ment effect.9 Providing that a trial is large enough,
randomization will ensure that the intervention and
control group are similar with regard to known and
unknown confounders [10]. As expected, our study
showed that taking into account between-centre differ-
ences did not affect statistical significance.
Several explanations can be given for our findings.
First, differences in outcome between centres in RCTs
may be caused by patient characteristics, which we
adjusted for in this analysis. We may not expect that
patient characteristics result in differences in treatment
effect between centres if the treatment is assumed to
work for all patients included in the trial. Secondly there
may be differences in care. If these only affect the base-
line event rate (e.g. fewer ICU capacity) the treatment
effect is not likely to be influenced. In contrast there
could be differences in care interacting with the treat-
ment, e.g. if time to hospital arrival is structurally longer
in some places, an acute treatment may be less effective.
If such an interaction is expected, it would usually be
captured in inclusion criteria, such as inclusion within a
certain time after injury. In our study we found large dif-
ferences in outcome between the centres but limited
variability in the treatment effect. In other words, there
was no substantial interaction between centre and treat-
ment, although such an interaction might have been
expected since the CRASH trial comprised an acute
treatment and was conducted in low- to high- income
countries. This is also an important finding from the per-
spective of standardisation of care in trials, which some
consider very important [9]. Our study suggests that if
non-standardized care only influences the absolute risk
and does not interact with the treatment, there is no rea-
son to put much effort in standardizing care.
We consider our results to be applicable to drug inter-
ventions, which work on physiological mechanisms. Trials
investigating a more complex intervention such as surgery
or a complex treatment strategy may be more sensitive to
differences in quality of care. The effect of outcome differ-
ence on treatment effect is not expected to be related to
the magnitude of the treatment effect. We recognize that
further studies are required to confirm or refute these find-
ings for other types of interventions and for other diseases.
Moreover it is crucial to think in advance on the mechan-
ism of the treatment, and whether heterogeneity or homo-
geneity of the treatment effect by centre is expected.
In this study we have assessed heterogeneity of the
treatment effects on a relative scale, but we can also use
Table 3 Estimated unadjusted treatment effects (odds ratio (OR) and p value) on 14 day mortality with different
approaches taking into account between-centre differences
Approach Model OR unadjusted P value tx
effect
-Uniform treatment effect over centres
-No adjustment for between-centre
differences
Fixed effect logistic regression 1.22 0.00010
-Uniform treatment effect over centres
-Adjustment for between-centre differences
Random effect logistic regression with random
intercept
1.24 0.00003
-Varying treatment effect over centres
-Adjustment for between-centre differences
Random effect logistic regression with random slope 1.22 (95% range: 1.17-
1.26)
0.00029
Figure 1 Differences between centres in mortality, adjusted for
age, GCS, pupil reactivity and treatment in a random effects
model. A centre with average mortality has log odds 0, a positive
log odds indicates higher mortality. Lines indicate 95% posterior
interval.
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an absolute scale (risk difference). We found that there
is no heterogeneity on the relative scale, despite hetero-
geneity in the absolute risks per centre. This combina-
tion implies that there is heterogeneity in treatment
effects on an absolute scale, which is important to rea-
lize when considering treatment for individuals [14].
The demonstration of hetero- or homogeneity in
treatment effects by country or centre in the single
study is conceptually the same as demonstration hetero-
or homogeneity is a meta-analysis. The CRASH trial
could be seen as a prospective meta-analysis of 40 trials
in 40 different countries. A simple way showing the het-
erogeneity in treatment effects would be to present the
results of a forest plot meta-analysis and test for hetero-
geneity. This was done for the CRASH trial (data not
shown), also not indicating heterogeneity.
Our finding that between-centre differences were not
explained by patient characteristics corresponds to pre-
vious studies in TBI.8 Part of the between-centre differ-
ences were actually between-county differences. This
could be an indication of centre-differences being
caused by structural differences between countries such
as availability of resources and organisation of trauma
care. The exact explanation of outcome differences
between centres and countries requires further study.
Our study has some limitations. First, we did not con-
sider differences in data quality between the centres,
which might affect the estimated treatment effect [7].
Second, the CRASH might be considered an exception
in the sense that the treatment was harmful. However, it
is unlikely that our results would depend on the direc-
tion of the treatment effect.
Conclusion
Our study shows that there were large between centre
differences in the CRASH trial, which had no clinically
meaningful effect on the estimated treatment effect.
Between-centre differences do not necessarily affect the
chances of demonstrating a treatment effect, which sup-
ports the conduct of large, multi-centre trials.
Appendix 1
Random effect logistic regression with random intercept
for centre
Logit (p(Yij = 1)) = β0 + (u0j + e0ij) (1)
withYij the outcome for patient i in centre j, b0 the
intercept, u0j the random intercept for the centre, and
e0ij the residuals. The random intercepts are assumed to
be normally distributed with τ20j = var(u0j).
Random effect logistic regression with random inter-
cepts for centre and country
Logit (p(Yij = 1)) = β0 + (u0j + u0k + e0ijk) (2)
With u0k the random intercept for the country, and
e0ijk the residuals. The random intercepts are assumed
to be normally distributed with τ20j = var(u0j) and τ
2
0kj =
var(u0k).
Random effect logistic regression with random intercept
for centre, including patient characteristics
Logit (p(Yij = 1)) = β0 + β1xij + (u0j + e0ij) (3)
with patient characteristics xij
Range of the centre effects
95% centre effect range = exp(1.96 ∗ τ0j); exp(1.96 ∗ −τ0j) (4)
Fixed effect logistic regression
Logit (p(Yij = 1)) = β0 + β1xij + eij (5)
with xij the treatment and b1 the treatment effect.
Random effect logistic regression with random intercept
for centre, including treatment
Logit (p(Yij = 1)) = β0 + β1xij + (u0j + e0ij) (6)
with xij the treatment and b1 the treatment effect, and
random intercept u0j
Random effect logistic regression with random slope of
the treatment effect per centre
Logit (p(Yij = 1)) = β0 + β1xij + (u1j + e1ij) (7)
Figure 2 Between-centre differences in treatment effect, in a
random effect model. The overall treatment effect is log odds =
0.20 (OR = 1.22). Lines indicate 95% posterior interval.
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with u1j as the random slope. The random slopes are
assumed to be normally distributed with τ21j = var(u1j)
Random effect logistic regression with random intercept
for centre and random slope of the treatment effect per
centre
Logit (p(Yij = 1)) = β0 + β1xij + (u0j + u1j + e0ij + e1ij) (8)
Range of the estimated treatment effect across centres
95% treatment effect range = exp(β1 + 1.96 ∗ τ1j); exp(β1 + 1.96 ∗ −τ1j) (9)
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